Literature DB >> 2429968

Comparison of bleomycin and peplomycin toxicity on clonogenic tumor cells from various human tumors.

H A Neumann, H M Runge, H H Fiebig, R Engelhardt, G W Löhr.   

Abstract

The cytotoxic effect of bleomycin and peplomycin was compared using a methylcellulose monolayer assay for the cultivation of human tumor cells. In 3 out of 4 samples from human malignant melanomas peplomycin proved to be more cytotoxic than bleomycin. Peplomycin was more cytotoxic than bleomycin in 1 of 5 myosarcoma samples, whereas 2 samples from squamous cell carcinomas of the lung showed identical dose response curves. In 1 carcinoma of the gall bladder peplomycin was more toxic than bleomycin.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2429968     DOI: 10.1007/bf00404401

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  6 in total

1.  Development of new bleomycins with potential clinical utility.

Authors:  W Tanaka
Journal:  Jpn J Antibiot       Date:  1977-12

2.  Human tumor colony assay and chemosensitivity testing.

Authors:  S E Salmon
Journal:  Cancer Treat Rep       Date:  1984-01

3.  Chemotherapy of advanced prostatic cancer with peplomycin.

Authors:  K Koiso; T Niijima
Journal:  Prostate Suppl       Date:  1981

4.  Potentiation of the cytostatic effect of bleomycin on L5178y mouse lymphoma cells by pepleomycin.

Authors:  W E Müller; M Geisert; R K Zahn; A Maidhof; M Bachmann; H Umezawa
Journal:  Eur J Cancer Clin Oncol       Date:  1983-05

5.  Tumor colony formation from human spontaneous tumors in a methylcellulose monolayer system.

Authors:  H A Neumann; G W Löhr; A A Fauser
Journal:  Res Exp Med (Berl)       Date:  1984

6.  Synergistic effect of peplomycin in combination with bleomycin on L5178y mouse lymphoma cells in vivo.

Authors:  W E Müller; R K Zahn; A Maidhof; H C Schröder; M Bachmann; H Umezawa
Journal:  J Antibiot (Tokyo)       Date:  1984-03       Impact factor: 2.649

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.